10-Q: Oragenics Secures Funding, Advances Brain Injury Drug

Oragenics reports significant capital raise and progress on its lead neurological drug candidate ONP-002, while addressing ongoing financial challenges and regaining NYSE compliance.

Summary

• Oragenics, Inc. is a development-stage biopharmaceutical company focused on nasally delivered therapies for neurological conditions and infectious diseases, with its lead product candidate, ONP-002, targeting mild traumatic brain injury (mTBI or concussion).
• The company reported a net loss of $7,555,617 for the nine months ended September 30, 2025, compared to $7,218,795 for the same period in 2024.
• Cash and cash equivalents significantly increased to $11,403,766 as of September 30, 2025, from $864,840 at December 31, 2024, primarily due to financing activities.
• Total stockholders' equity improved to $9,831,436 as of September 30, 2025, from a deficit of $(211,885) at December 31, 2024.
• Research and development (R&D) expenses decreased by 29.7% to $1,722,115 for the nine months ended September 30, 2025, reflecting a shift in focus to ONP-002 regulatory submissions and manufacturing readiness.
• General and administrative (G&A) expenses increased by 8.2% to $5,142,087 for the nine months ended September 30, 2025, largely due to higher legal and professional fees, including a $700,000 accrual for a legal settlement.
• The company successfully completed a public offering of Series H Convertible Preferred Stock and warrants on July 2, 2025, generating net proceeds of approximately $15.2 million.
• Oragenics regained compliance with NYSE American stockholders' equity requirements on October 20, 2025, leading to the removal of the non-compliant indicator.
• The company's independent registered public accounting firm included an explanatory paragraph raising substantial doubt about its ability to continue as a going concern for the year ended December 31, 2024, which persists despite recent financing.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant capital raise, which substantially improved the company's liquidity and extended its cash runway, and the regaining of NYSE compliance. This provides a clearer path forward for the lead product candidate, ONP-002. However, persistent net losses, a substantial accumulated deficit, and the ongoing 'going concern' qualification temper the overall positive outlook, indicating continued high risk.

Positives

• Successfully raised approximately $15.2 million in net proceeds from the issuance of Series H Preferred Stock and warrants in July 2025, significantly bolstering liquidity.
• Regained compliance with NYSE American stockholders' equity requirements on October 20, 2025, removing the non-compliant indicator.
• Cash and cash equivalents increased substantially to $11.4 million as of September 30, 2025, from $0.86 million at December 31, 2024, extending the funding runway through the first half of 2026.
• Total stockholders' equity improved from a deficit of $(211,885) at December 31, 2024, to a positive $9.8 million at September 30, 2025.
• R&D expenses decreased by 29.7% for the nine months ended September 30, 2025, reflecting a strategic shift to focus on the lead ONP-002 program and completion of non-core work.
• Settled a legal dispute with Ladenburg Thalmann & Co. Inc. for $700,000, resolving a significant contingency.

Negatives

• Incurred a net loss of $7,555,617 for the nine months ended September 30, 2025, and an accumulated deficit of $224,341,789 as of September 30, 2025.
• The independent registered public accounting firm's report for the year ended December 31, 2024, included an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern, which remains a concern.
• General and administrative expenses increased by 8.2% for the nine months ended September 30, 2025, partly due to higher legal and professional fees, including a $700,000 legal settlement accrual.
• Interest expense increased significantly by 4,027.88% for the nine months ended September 30, 2025, primarily due to amortization of debt discount and closing costs related to a short-term promissory note.

Risks

• The Certificate of Designation for Series H Convertible Preferred Stock contains anti-dilution provisions that may result in a reduction of the conversion price, leading to an indeterminate number of common shares being issued upon conversion and greater dilution to existing shareholders.
• There is no floor price on the conversion price for Series H Preferred Stock, making it difficult to determine the total number of shares issuable upon conversion and potentially requiring an increase in authorized shares.
• The company will need to raise additional capital in the future to complete the development and commercialization of its product candidates and sustain operations beyond the first half of 2026.
• The auditor has expressed substantial doubt about the company's ability to continue as a going concern, which may depress the common stock price and make future financing more challenging.
• Future sales of common stock or other equity securities will result in dilution to existing common shareholders and could adversely affect the market price of the common stock.
• Warrants issued in connection with the Series H Preferred Stock offering may not be exercised if the market price of the common stock remains below the conversion price, limiting additional proceeds to the company.

Future Outlook

The company expects to continue incurring substantial expenses as it advances the development of ONP-002, its lead product candidate for mild traumatic brain injury. It plans to initiate a Phase IIa clinical trial in Australia in Q4 2025, begin IND-enabling work for a Phase IIb trial in the United States in Q4 2026, and commence manufacturing of additional ONP-002 clinical material. A Phase III trial is estimated to start in Q4 2027. While recent financing extends the cash runway through the first half of 2026, additional capital will be required to complete planned clinical trials, regulatory filings, and future commercialization efforts. The company will seek further equity and debt financings, as well as strategic alliances.

Management Comments

• "Based on our available cash of September 30, 2025, we believe our current working capital will be sufficient to fund planned operations for at least the next twelve months from the date of this filing, taking into account the net proceeds from the July 2025 financing."
• "We believe that this financing meaningfully extends our ability to execute on our near-term operating objectives, including continued development of ONP-002."
• "While this financing mitigates some of the liquidity risk, substantial doubt about our ability to continue as a going concern continues to exist unless and until we obtain additional capital to fund operations beyond the current planning horizon."

Industry Context

Oragenics operates in the highly capital-intensive and high-risk biopharmaceutical industry, specifically focusing on development-stage assets for neurological conditions. The company's strategy of advancing a novel therapeutic (ONP-002) for an unmet medical need like mTBI aligns with broader industry trends seeking innovative solutions for complex diseases. However, as a development-stage company, it faces significant challenges common to the sector, including substantial R&D costs, reliance on external funding, and lengthy regulatory approval processes. The focus on nasal delivery for direct brain accessibility represents a differentiated approach within the neurosteroid therapeutic space.

Legal Proceedings

• The company settled a dispute with Ladenburg Thalmann & Co. Inc. for $700,000. This amount was accrued as of September 30, 2025, and paid on October 17, 2025, in full satisfaction of the matter, which involved a disputed fee related to an asset purchase.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity issuances, especially given the anti-dilution provisions of the Series H Preferred Stock, which could lead to an indeterminate number of common shares being issued.
• Existing common shareholders may experience a depressed stock price due to the anti-dilution protection and the ongoing 'going concern' doubt.
• Employees have been impacted by headcount reductions, as reflected in the decrease in salaries and benefits under G&A expenses.
• Creditors (holders of the promissory note) have been repaid, demonstrating the company's ability to meet short-term debt obligations following the capital raise.

Next Steps

• Initiate Phase IIa clinical trial for ONP-002 in Australia (estimated Q4 2025 start).
• Begin IND-enabling work to support a Phase IIb trial for ONP-002 in the United States (estimated Q4 2026 start).
• Commence manufacturing of additional ONP-002 clinical material.
• Plan for a Phase III trial for ONP-002 (estimated Q4 2027 start).
• Seek additional equity and debt financings, as well as strategic alliances, to fund operations beyond the current planning horizon.

Key Dates

Recommendation

While Oragenics has significantly improved its liquidity through a recent capital raise and regained NYSE compliance, these positive developments are largely offset by the company's persistent net losses, substantial accumulated deficit, and the auditor's ongoing 'going concern' qualification. The company remains a high-risk, development-stage biopharmaceutical entity with significant future capital requirements and potential for substantial shareholder dilution. For existing investors, holding the stock to monitor the progress of ONP-002's clinical trials and future financing efforts is warranted, given the extended cash runway. However, for new investors, the inherent risks associated with a pre-revenue biopharma company facing 'going concern' issues suggest caution, making a 'hold' or 'na' recommendation more appropriate than a 'buy' at this stage.

Keywords

Biopharmaceutical, ONP-002, Mild Traumatic Brain Injury, Concussion, Neurological Conditions, SEC Filing, 10-Q, Clinical Trials, Series H Preferred Stock, Capital Raise, Going Concern, NYSE American, Stock Split, Dilution